ANI Pharmaceuticals (NASDAQ:ANIP) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report published on Monday,Benzinga reports. The firm currently has a $94.00 price target on the specialty pharmaceutical company’s stock.

Other equities analysts also recently issued research reports about the stock. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. Finally, Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They issued an “outperform” rating and a $80.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $79.00.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $59.68 on Monday. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The company’s 50 day moving average is $57.42 and its 200 day moving average is $58.10. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a market cap of $1.26 billion, a PE ratio of -108.51 and a beta of 0.74.

Insider Activity

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the transaction, the senior vice president now owns 68,624 shares in the company, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,300 shares of company stock worth $584,009 in the last quarter. Corporate insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Pacer Advisors Inc. lifted its holdings in ANI Pharmaceuticals by 23,259.8% in the 3rd quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company’s stock valued at $33,907,000 after purchasing an additional 565,910 shares in the last quarter. Millennium Management LLC lifted its holdings in ANI Pharmaceuticals by 89.3% in the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock valued at $55,437,000 after purchasing an additional 473,097 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of ANI Pharmaceuticals by 159.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after acquiring an additional 340,854 shares during the last quarter. abrdn plc acquired a new stake in shares of ANI Pharmaceuticals in the 4th quarter worth $13,155,000. Finally, Bank of Montreal Can acquired a new stake in shares of ANI Pharmaceuticals in the 3rd quarter worth $13,043,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.